Aristizabal-Bernal BH, Rincón-Caballero OL, Cano-Romero MA

Idioma: Español
Referencias bibliográficas: 41
Paginas: 91-100
Archivo PDF: 529.04 Kb.

RESUMEN

Introducción: las infecciones pulmonares son comunes en los pacientes inmunocomprometidos. La carga viral de citomegalovirus se utiliza de rutina para determinar en qué momento se debe iniciar la terapia preventiva en hospederos inmunocomprometidos, diagnosticar enfermedad activa y supervisar la repuesta a una terapia implementada.
Objetivo: describir el valor de la carga viral de citomegalovirus en líquido de lavado bronquioalveolar vs. sangre periférica en población pediátrica con signos de infección respiratoria.
Material y Métodos: estudio descriptivo, observacional de 16 pacientes pediátricos y 19 episodios, a quienes se les realizó, de manera simultánea, la carga viral de citomegalovirus en sangre y lavado bronquioalveolar.
Resultados y Conclusiones: todas las cargas virales de citomegalovirus realizadas en lavado bronquioalveolar fueron positivas y en general se obtuvieron valores más elevados que en sangre, lo que sugiere una mayor sensibilidad de la prueba cuando se realiza en este tipo de muestra, en pacientes con sospecha clínica de infección respiratoria por citomegalovirus, lo cual la convierte en una ayuda diagnóstica importante según lo muestran los resultados obtenidos.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Snydman DR, Limaye AP, Potena L, Zamora MR. Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant Proc. 2011;43(3 Suppl):S1-S17.

2. Schlischewsky E, Fuehner T, WRNAecke G, Welte T, Haverich A, Ganzenmueller T, Heim A, Gottlieb J. Clinical significance of quantitative cytomegalovirus detection in bronchoalveolar lavage fluid in lung transplant recipients. Transpl Infect Dis. 2013;15:60-69.

3. Agut H, Bonnafous P, Gautheret-Dejean A, Laboratory and clinical aspects of human herpesvirus 6 infections. Clin Microbiol Rev. 2015;28(2):313-35.

4. Vilibic-Cavlek T, Kolaric B, Ljubin-Sternak S, Kos M, Kaic B, Mlinaric-Galinovic G. Prevalence and dynamics of cytomegalovirus infection among patients undergoing chronic hemodialysis. Indian J Nephrol. 2015;25(2):95-8.

5. Hodson EM, Craig JC, Strippoli GF, Webster AC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2013 Feb 28;2:CD003774. doi: 10.1002/14651858. CD003774.

6. Drew WL. Laboratory diagnosis of cytomegalovirus infection and disease in immunocompromised patients. Curr Opin Infect Dis. 2007;20(4):408–411.

7. Travi G and Pergam S.A. Cytomegalovirus Pneumonia in Hematopoietic Stem Cell Recipients. J Intensive Care Med. 2014;29(4):200-12.

8. Aitken C, Barrett-Muir W, Millar C, et al. Use of molecular assays in diagnosis and monitoring of cytomegalovirus disease following renal transplantation. J Clin Microbiol. 1999;37(9):2804-7.

9. Kraft CS, Armstrong WS, Caliendo AM. Interpreting quantitative cytomegalovirus DNA testing: understanding the laboratory perspective. Clin Infect Dis. 2012;54(12):1793-7.

10. Tong CY, Cuevas LE, Williams H, Bakran A. Comparison of two commercial methods for measurement of cytomegalovirus load in blood samples after renal transplantation. J Clin Microbiol. 2000;38(3):1209-13.

11. Humar A, Gregson D, Caliendo AM, et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation.1999;68(9):1305-11.

12. Razonable RR, Brown RA, Wilson J, et al. The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. Transplantation. 2002;73(6):968-73.

13. Engelmann I, Petzold DR, Kosinska A, Hepkema BG, Schulz TF, Heim A. Rapid quantitative PCR assays for the simultaneous detection of herpes simplex virus, varicella zoster virus, cytomegalovirus, Epstein–Barr virus, and human herpesvirus 6 DNA in blood and other clinical specimens. J Med Virol. 2008;80(3):467-477.

14. Abdul-Ali D, Kraft CS, Ingersoll J, et al. Cytomegalovirus DNA stability in EDTA anti-coagulated whole blood and plasma samples. J Clin Virol. 2011;52(3):222-4.

15. Chemaly RF, Yen-Lieberman B, Chapman J, et al. Clinical utility of cytomegalovirus viral load in bronchoalveolar lavage in lung transplant recipients. Am J Transplant. 2005;5(3):544-548.

16. Lisboa LF, Asberg A, Kumar D, et al. The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response. Transplantation. 2011;91(2):231-6.

17. Kerschner H, Bauer C, Schlag P, et al. Clinical evaluation of a fully automated CMV PCR assay. J Clin Virol. 2011;50(4):281-6.

18. Caliendo AM, Ingersoll J, Fox-Canale AM, et al. Evaluation of real-time PCR laboratory-developed tests using analytespecific reagents for cytomegalovirus quantification. J Clin Microbiol. 2007;45(6):1723-7.

19. Caliendo AM, Yen-Lieberman B, Baptista J, et al. Comparison of molecular tests for detection and quantification of cell-associated cytomegalovirus DNA. J Clin Microbiol. 2003;41(8):3509-13.

20. Caliendo AM, St George K, Allega J, et al. Distinguishing cytomegalovirus (CMV) infection and disease with CMV nucleic acid assays. J Clin Microbiol. 2002;40(5):1581-6.

21. KulkRNAi A, Westmoreland D, Fox JD. Molecular-based strategies for assessment of CMV infection and disease in immunosuppressed transplant recipients. Clin Microbiol Infect. 2001;7(4):179-86

22. Humar A, Kumar D, Boivin G, Caliendo AM. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis. 2002;186(6):829-33.

23. Gerna G, Baldanti F, Lilleri D, Parea M, Alessandrino E, Pagani A, et al. Human cytomegalovirus immediateearly mRNA detection by nucleic acid sequence based amplification as a new parameter for preemptive therapy in bone marrow transplant recipients. J Clin Microbiol. 2000;38(5):1845-53.

24. Revello MG, Gerna G. Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin Microbiol Rev. 2002;15(4):680-715.

25. Weinberg A, Hodges TN, Li S, et al. Comparison of PCR, antigenemia assay, and rapid blood culture for detection and prevention of cytomegalovirus disease after lung transplantation. J Clin Microbiol. 2000;38(2):768-72.

26. Hassan-Walker AF, Kidd IM, Sabin C, et al. Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: relationship with donor/recipient CMV serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATG). J Med Virol. 1999;58(2):182-7.

27. Caliendo AM, St George K, Kao SY, et al. Comparison of quantitative cytomegalovirus (CMV) PCR in plasma and CMV antigenemia assay: clinical utility of the prototype AMPLICOR CMV MONITOR test in transplant recipients. J Clin Microbiol. 2000;38(6):2122-7.

28. Kerschner H, Bauer C, Schlag P, et al. Clinical evaluation of a fully automated CMV PCR assay. J Clin Virol. 2011;50(4):281-6.

29. Schäfer P, Tenschert W, Gutensohn K, Laufs R. Minimal effect of delayed sample processing on results of quantitative PCR for cytomegalovirus DNA in leukocytes compared to results of an antigenemia assay. J Clin Microbiol. 1997;35(3):741-4.

30. Abdul-Ali D, Kraft CS, Ingersoll J, et al. Cytomegalovirus DNA stability in EDTA anti-coagulated whole blood and plasma samples. J Clin Virol. 2011;52(3):222-4.

31. Razonable RR, Brown RA, Espy MJ, et al. Comparative quantitation of cytomegalovirus (CMV) DNA in solid organ transplant recipients with CMV infection by using two high-throughput automated systems. J Clin Microbiol. 2001;39(12):4472-6.

32. Smith TF, Espy MJ, Mandrekar J, et al. Quantitative realtime polymerase chain reaction for evaluating DNAemia due to cytomegalovirus, Epstein-Barr virus, and BK virus in solid-organ transplant recipients. Clin Infect Dis. 2007;45:1056-61.

33. Ferreira-Gonzalez A, Fisher RA, Weymouth LA, et al. Clinical utility of a quantitative polymerase chain reaction for diagnosis of cytomegalovirus disease in solid organ transplant patients. Transplantation. 1999;68(7):991-6.

34. Sia IG, Wilson JA, Groettum CM, et al. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis. 2000;181:717-20.

35. Razonable RR, Brown RA, Wilson J, et al. The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. Transplantation. 2002;73:968-73.

36. Costa C, Curtoni A, Sidoti F, Balloco C, Simeone S, Mantovani S, Piasentin Alessio E, Libertucci D, Delsedime L, Solidoro P, Baldi S, Cavallo R.Detection of human cytomegalovirus in transbronchial biopsies from lung transplant recipients. Arch Virol. 2013;158(7):1461-5.

37. Costa C, Delsedime L, Solidoro P, Curtoni A, Bergallo M, Libertucci D, Baldi S, Rinaldi M, Cavallo R. Herpesviruses detection by quantitative real-time polymerase chain reaction inbronchoalveolar lavage and transbronchial biopsy in lung transplant: viral infections and histopathological correlation. Transplant Proc. 2010;42(4):1270-4.

38. Jouneau S, Poineuf JS, Minjolle S, Tattevin P, Uhel F, Kerjouan M, Le Hô H, Desrues B.Which patients should be tested for viruses on bronchoalveolar lavage fluid? Eur J Clin Microbiol Infect Dis. 2013;32(5):671-7.

39. Pang XL, Fox JD, Fenton JM, et al. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant. 2009;9:258-68.

40. Wiita AP, Roubinian N, Khan Y, Chin-Hong PV, Singer JP, Golden JA, Miller S. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis. Transpl Infect Dis. 2012;14(3):248-58.

41. Henke-Gendo C, Ganzenmueller T, Kluba J, Harste G, Raggub L, Heim A. Improved quantitative PCR protocols for adenovirus and CMV with an internal inhibition control system and automated nucleic acid isolation. J Med Virol. 2012;84(6):890-896.